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Abstract
Purpose We aimed to assess the factor structure, internal con-
sistency, test-retest reliability, and construct validity of the
European Portuguese version of the Pittsburgh Sleep Quality
Index (PSQI) in breast cancer patients.
Methods This study was based on a cohort of breast cancer
patients, among whom the PSQI was used to measure sleep
quality three years after cancer diagnosis (N = 474). A sample
of 62 participants underwent additional PSQI testing, wore a
wrist actigraph for five consecutive days, and was reevaluated
with the PSQI after one month. A confirmatory factor analy-
sis, considering the components suggested by the principal
component analysis (PCA), was performed to determine mod-
el fit. To evaluate internal consistency and test-retest reliabil-
ity, Cronbach’s alpha and intraclass correlation coefficient
(ICC) were calculated, respectively. To assess construct valid-
ity, Spearman’s correlation coefficients were computed be-
tween PSQI scores and actigraphy measures and other theo-
retical related constructs.
Results PCA suggested one or two components. The latter
showed better fit to the data, though the two factors were
strongly correlated (r = 0.76) and internal consistency was
not satisfactory for one of the factors. Regarding the one-
factor model, internal consistency (Cronbach’s alpha = 0.70)
and test-retest reliability (ICC = 0.76) were adequate. Sleep
duration, habitual sleep efficiency, and sleep disturbance di-
mensions were significantly correlated with the corresponding
actigraphy measures; the PSQI global score derived from the
one-factormodel wasmore strongly correlatedwith subjective
sleep complaints (r ≥ 0.60).
Conclusions The unidimensional construct of the European
Portuguese version of the PSQI showed adequate reliability
and validity among breast cancer patients.
Keywords Actigraphy . Breast neoplasms . Principal
component analysis . Psychometrics . Sleep
Introduction
Sleep complaints have been reported to affect up to 65% of
breast cancer patients [1–3], being more frequent than in pa-
tients with other oncological diseases [4, 5] or in the general
population [6, 7]. Among breast cancer patients, poor sleep
quality was shown to be an important contributor to low
health-related quality of life (QoL) [3, 8] and to be correlated
with other physical and psychological outcomes, including
fatigue [9], anxiety, and depression [10].
The Pittsburgh Sleep Quality Index (PSQI) is a self-
administered questionnaire to assess sleep quality [11], com-
monly used among breast cancer patients. A systematic re-
view on the psychometric properties of this instrument
showed that it has good internal consistency for within- and
between-group comparisons, but there was scarce information
on test-retest reliability [12]. However, the correlation be-
tween PSQI scores and the corresponding measures derived
from polysomnography or actigraphy were generally poor
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[12]. Furthermore, previous studies in different populations
have shown that the PSQI might be better represented by a
two- or a three-factor model [13–16], rather than the original
one-factor structure; studies among breast cancer patients
yielded inconsistent results [14, 17]. Otte el al. [14] reported
that a two-factor model had a better fit than the original one-
factor or a three-factor solution. Their study yielded a Bsleep
efficiency^ factor composed by the sleep duration and habit-
ual sleep efficiency components and a Bperceived sleep
quality^ factor, with the remaining PSQI components. On
the contrary, Ho et al. [17] described that a revised one-
factor model, with a residual covariance between sleep dura-
tion and habitual sleep efficiency, was the best solution,
supporting the original unidimensional structure of the PSQI.
Two studies evaluated the psychometric properties of the
PSQI in Portuguese populations [18, 19]; one reported prelim-
inary data from a sample of undergraduates and master degree
students [19], and the other evaluated a sample of community-
dwelling adults [18], yielding values of internal consistency
for the unidimensional solution (Cronbach’s alpha) of 0.65
and 0.70, respectively. However, the factor structure of the
PSQI or its test-reliability was not addressed in any of these
previous studies, and none of them investigated its construct
validity using an objective measure of sleep (e.g., actigraphy
or polysomnography). Therefore, we aimed to assess the fac-
tor structure, internal consistency, test-retest reliability, and
construct validity of the European Portuguese version of the
PSQI, in breast cancer patients, three years after cancer
diagnosis.
Methods
Participants
Participants were breast cancer patients enrolled in 2012 in a
prospective cohort study designed to assess neurological com-
plications and patient reported outcomes related with cancer
and its treatment, among women with newly diagnosed breast
cancer. The study protocol has been described in detail else-
where [20]. Briefly, patients proposed for surgery were con-
secutively recruited among those admitted to the Breast Clinic
of the Portuguese Institute of Oncology of Porto (IPO-Porto).
We excluded women treated with chemotherapy and/or radio-
therapy in the chest or axillary areas for other primary cancer,
those who had received any treatment for breast cancer before,
and those considered less likely to be able to cooperate due to
cognitive impairment (score lower than 17, or lower than 16
for women over 65 years, in the Montreal Cognitive
Assessment [21]).
The present investigation was based on data from 474
women evaluated three years after breast cancer diagnosis
(T0) and on data derived from evaluations in two later
moments (T1 and T2) of a convenience sample (N = 62) of
these participants, selected mostly among those living closer
to IPO-Porto (Fig. 1).
At T0, socio-demographic data were collected using a
structured questionnaire and clinical records were reviewed
for cancer stage and breast cancer treatments. Sleep quality
was evaluated using the PSQI [11]. Anxiety and depression
were measured through the Hospital Anxiety and Depression
scale [22]. QoL was assessed using the questionnaire of the
European Organization for the Research and Treatment of
Cancer [23]; for the purposes of the present analysis, the glob-
al health status/QoL, insomnia and fatigue subscales were
used to address overall QoL, subjective sleep complaints and
fatigue, respectively. In the global health status/QoL subscale,
higher scores represent better QoL, while in the remaining
subscales or instruments, higher scores correspond to worse
outcomes.
At T1, a sample of 62 participants underwent additional
PSQI evaluation and were invited to wear a wrist actigraph
for five consecutive days. After one month (T2), these patients
were contacted by phone to be reevaluated with the PSQI
(Fig. 1).
Sleep measures
Pittsburgh Sleep Quality Index
The PSQI was designed to measure sleep quality over a one-
month interval. It includes 19 self-rated questions that gener-
ate seven component scores: subjective sleep quality, sleep
latency, sleep duration, habitual sleep efficiency, sleep distur-
bances, use of sleep medication, and daytime dysfunction.
Component scores (range 0 to 3) are summed to provide a
global sleep quality score (range 0 to 21); a score greater than
five indicates poor sleep quality [11]. For the present study, we
used a previously published European Portuguese version of
the PSQI [24].
Actigraphy
Participants were asked to use an actigraph (Actiwatch 2;
Phillips Respironic, USA) for five consecutive days, always
including three weekdays and the weekend, with the instruc-
tion to remove it only for swimming. The Actiwatch 2
actigraph is a wrist monitor that includes an accelerometer to
measure movement activity and a photometer to measure light
exposure; the latter is used to assist in the interpretation of
movement activity. Epochs of one-min light exposure and
movement were transferred to a computer and analyzed using
the Actiware-Sleep 5.0 analysis software (Phillips Respironic,
USA). For a more accurate interpretation of the movement
activity, participants fulfilled a sleep diary while wearing the
actigraph and were asked to keep record of any period in
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which it was removed. For the purpose of the present analysis,
averages of four actigraphy sleep parameters were computed:
sleep latency (time until falling asleep), total sleep time (actual
sleep time), sleep efficiency (percent of time in bed spent
sleeping), and wake time after sleep onset (WASO, total
amount of time awake during the night after falling asleep).
The Actiwatch 2 actigraph was previously used in valida-
tion studies in other populations (e.g., adult volunteers free of
sleep disorders [25], adult patients with low back pain [26],
children and adolescents scheduled for a clinical evaluation of
s l e ep [27 ] ) . The ag r eemen t w i t h r e su l t s f r om
polysomnography was shown to be close to 90% [25–27].
Statistical analysis
Sample characteristics are presented as counts and proportions
for categorical variables, mean and standard deviation (SD)
for quantitative variables with approximately symmetrical dis-
tributions, and median and percentile 25 and 75 (P25-P75) for
quantitative variables with markedly asymmetrical
distributions.
Participants selected for actigraphy were compared with
the remaining cohort, regarding socio-demographic and clin-
ical characteristics, using the Mann-Whitney or the chi-square
tests, as applicable.
Principal component analysis (PCA) was performed using
data from T1; confirmatory factor analysis (CFA) and internal
consistency analysis were performed using data from T0; con-
struct validity was assessed through data retrieved at T0 (PSQI
measures, sleep complaints, fatigue, anxiety, depression, and
global health status/QoL) and T1 (actigraphy measures of
sleep latency, total sleep time, sleep efficiency and WASO);
and test-retest reliability was evaluated using data both from
T1 and T2, as depicted in Fig. 1.
A PCA was performed using the seven PSQI component
scores, to understand the underlying structure of the PSQI.
The acceleration factor and the optimal coordinate index were
assessed to determine the number of components to retain
[28]. The PSQI components with absolute factor loading of
0.40 or higher were interpreted as having a meaningful con-
tribution to the corresponding underlying factor.
A CFA was performed to assess model fit of the factor
structure obtained from the PCA. It was evaluated using the
chi-square goodness of fit test (χ2), the chi-square per degree
of freedom (χ2/df), the standardized root mean squared resid-
ual (SRMR), the root mean square error of approximation
(RMSEA), the comparative fit index (CFI) and the Tucker-
Lewis index (TLI). Commonly used guidelines suggest
SRMR at 0.08 or lower, RMSEA at 0.07 or lower, CFI and
TLI at 0.95 or greater and non-significant values of χ2 or χ2/df
between 2 and 3 to be considered adequate model fit [29].
To evaluate the internal consistency, we calculated
Cronbach’s alpha and to further assess component internal
consistency, we computed the corrected item-total correlation.
To assess test-retest reliability, the intraclass correlation coef-
ficients (ICCs) were computed using a two-way mixed effects
model, treating the cases as a random factor, for each of the
seven components of the PSQI, for each factor, and for the
global score.
In order to assess construct validity, Spearman’s correlation
coefficients were computed between PSQI-derived scores and
actigraphy corresponding measures and other theoretically re-
lated constructs, namely sleep complaints, fatigue, anxiety,
depression, and global health status/QoL.
Fig. 1 Diagram describing the number of patients in each of the
evaluations performed. PSQI Pittsburgh Sleep Quality Index, P25
percentile 25, P75 percentile 75. Data on actigraphy is only available
for 61 patients, because one patient refused to use it because she felt it
worsened her sleep quality (superscript letter a)
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Statistical analyses were conducted using STATA®, ver-
sion 11.2 (StataCorp, College Station, TX, USA) and R, ver-
sion 3.0.1 (R Core Team, Vienna, Austria).
Results
Participants’ characteristics
At T0, participants had a mean (SD) age of 57.9 (10.8) years
and a median (P25–P75) of 6 (4–11) years of schooling. A
total of 6.5% had non-invasive breast cancer (ductal carcino-
ma in situ). Among the remaining patients, most were at stage
I (47.3%) and II (30.8%), whereas just over 15% were more
advanced (stage III, 14.8%; stage IV, 0.6%). Nearly half of the
women were submitted to mastectomy (49.6%) and one third
underwent axillary lymph node dissection (34.2%). At T0, the
mean (SD) PSQI score was 7.3 (4.3) and 61.4% of the partic-
ipants presented poor sleep quality.
Participants included in the T1 sample were significantly
younger than the remaining cohort (median: 55.2 vs. 58.5,
P = 0.018) and presented a lower proportion of poor sleep
quality at T0 (50.0 vs. 63.1%, P = 0.048), but there were no
significant differences regarding education (median 6 vs. 6
schooling years, P = 0.458) and cancer stage (stage 0/I 56.4
vs. 53.5%, P = 0.665).
Fig. 2 Confirmatory factor analysis for the a one-factor and b two-factor
models of the Pittsburgh Sleep Quality Index (PSQI) in breast cancer
patients (N = 474). CFI comparative fit index, PSQI Pittsburgh Sleep
Quality Index, RMSEA root mean square error of approximation, SRMR
standardized root mean squared residual, TLI Tucker-Lewis index. Ovals
identify latent variables. Rectangles represent the PSQI measured items.
Single-headed arrows represent loadings between each PSQI component
and the underlying factor. Double-headed arrows represent correlations
between PSQI items or between factors, as applicable.χ2 = 38.3 (df= 12),
p value < 0.005; χ2/df = 3.2; SRMR = 0.04; RMSEA = 0.07; CFI = 0.97;
TLI = 0.94 (superscript letter a). χ2 = 30.0 (df = 11), p value < 0.005; χ2/
df = 2.7; SRMR = 0.04; RMSEA = 0.06; CFI = 0.98; TLI = 0.95 (super-
script letter b)
Table 1 Principal component
analysis of the Pittsburgh Sleep
Quality Index (PSQI),
considering the one-component
and the two-component model
(N = 62)
PSQI components One-component model Two-component modela
PC1 PC2
Subjective sleep quality 0.79 0.67 0.42
Sleep latency 0.60 0.45 0.40
Sleep duration 0.62 0.82 −0.16
Habitual sleep efficiency 0.78 0.85 0.10
Sleep disturbance 0.67 0.41 0.60
Use of sleep medication 0.20 −0.22 0.73
Daytime dysfunction 0.46 0.15 0.64
% of explained variance 0.38 0.33 0.24
% of explained cumulative variance 0.38 0.33 0.57
PC principal component, PSQI Pittsburgh Sleep Quality Index
aVarimax with Kaiser Normalization rotation method. PSQI components presenting factor loadings of 0.40 or
higher with both PC were assumed to contribute to the PC with the highest factor loading
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Principal component analysis
Using the acceleration factor and the optimal coordinate index
as the extraction criterion for components, one or two compo-
nents, which accounted for a total of 38% or 57% of the
variance, respectively, were identified in the PCA (Table 1).
In the one-component solution, the use of sleep medication
PSQI component did not reliably load into the principal com-
ponent (PC) (absolute factor loading <0.40). In the two-
component solution, all the PSQI components have a mean-
ingful contribution on the corresponding PC; the PC1 includes
subjective sleep quality, sleep latency, sleep duration, and ha-
bitual sleep efficiency; and the PC2 includes sleep distur-
bance, use of sleep medication, and daytime dysfunction.
Confirmatory factor analysis
The CFA for the one-factor and two-factor models of the PSQI
are depicted in Fig. 2. In both solutions, the examination of
modification indices suggested that habitual sleep efficiency
was correlated with sleep duration and sleep latency compo-
nents. The two-factor model seems to provide a better fit than
the original one-factor model, as established by smaller values
of χ2/df (2.7 vs. 3.2) and higher values of TLI (0.95 versus
0.94). In the former the correlation between each PSQI com-
ponent and the underlying factor ranged from 0.22 to 0.88 and
in the latter from 0.43 to 0.91 in factor 1 and 0.26 to 0.52 in
factor 2. In the two-factor model, the correlation between fac-
tor 1 and factor 2 was high (0.76).
Score reliability
When considering all of the seven components together (one-
factor solution), the corrected item-total correlation ranged
from 0.22 to 0.62; the overall Cronbach’s alpha was 0.70
and increased to 0.75 when the use of use of sleep medication
component was omitted (Table 2). Considering the two-factor
solution, internal consistency was adequate for factor 1 but not
satisfactory for factor 2 (Cronbach’s alpha 0.78 vs. 0.28). The
corrected item-total correlation ranged from 0.49 to 0.70 in
factor 1 and from 0.16 to 0.21 in factor 2; removal of the use of
sleep medication component from factor 2 increased
Cronbach’s alpha to 0.38 (Table 2).
Test-retest reliability is described in Table 3. The within-
subject reliability was high for the use of sleep medication
PSQI component, for factor 2, and for the PSQI global score
derived from the one-factor model, and moderate for each of
the remaining individual components.
Table 2 Item-total correlation
with total score (N = 474) PSQI components Corrected item-total correlation Cronbach’s alpha if item deleted
One-factor
model
Two-factor model One-factor
model
Two-factor model
Factor
1
Factor
2
Factor
1
Factor
2
Subjective sleep quality 0.62 0.60 0.63 0.73
Sleep latency 0.50 0.49 0.64 0.78
Sleep duration 0.49 0.60 0.65 0.72
Habitual sleep
efficiency
0.62 0.70 0.60 0.66
Sleep disturbances 0.34 0.20 0.69 0.20
Use of sleep medication 0.22 0.16 0.75 0.38
Daytime dysfunction 0.27 0.21 0.70 0.14
Cronbach’s alpha 0.70 0.78 0.28
Table 3 Test-retest reliability for the seven Pittsburgh Sleep Quality
Index (PSQI) components, and for the one-factor and the two-factor
models (N = 60)
PSQI components ICCa (95%CI)
Subjective sleep quality 0.64 (0.46–0.77)
Sleep latency 0.56 (0.36–0.71)
Sleep duration 0.59 (0.40–0.73)
Habitual sleep efficiency 0.56 (0.36–0.71)
Sleep disturbance 0.46 (0.23–0.64)
Use of sleep medication 0.89 (0.82–0.93)
Daytime dysfunction 0.66 (0.48–0.78)
Factor 1 (two-factor model) 0.69 (0.53–0.80)
Factor 2 (two-factor model) 0.79 (0.67–0.87)
PSQI global score (one-factor model) 0.76 (0.62–0.85)
PSQI Pittsburgh Sleep Quality Index
a Intraclass correlation coefficients (ICCs) using an absolute agreement
and single measures definition and two-way mixed effects model
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Score validity
Correlations between the PSQI scores and actigraphy mea-
sures and other theoretical related constructs are reported in
Table 4. All of the specific actigraphy measures, except sleep
latency, were significantly correlated with the corresponding
PSQI scores (r ≥ |0.30|). Greater WASO and sleep efficiency
evaluated with the actigraphy were significantly associated
with lower sleep efficiency and greater sleep duration, respec-
tively, measured by the PSQI. Statistically significant correla-
tions were found between almost all of the theoretical related
constructs and measures derived from the PSQI. The strongest
associations were found between sleep complaints and both
factor 1 and PSQI global score (r ≥ 0.60).
Discussion
This study shows that a one-factor model has adequate inter-
nal consistency for within- and between-group comparisons
(Cronbach’s alpha = 0.70) and test-retest reliability
(ICC = 0.76) [30]. Although a two-factor model (factor 1
including subjective sleep quality, sleep latency, sleep dura-
tion, and habitual sleep efficiency; factor 2 including sleep
disturbance, use of sleep medication, and daytime dysfunc-
tion) had a better fit, the internal consistency was not satisfac-
tory for factor 2 (Cronbach’s alpha = 0.28).
To our knowledge, only two studies have addressed the
factor structure of the PSQI among breast cancer patients
[14, 17]. One study suggested that a two-factor model better
fit the data than the original solution, yielding a Bsleep
efficiency^ factor composed by the sleep duration and habit-
ual sleep efficiency components and a Bperceived sleep
quality^ factor, with the remaining components [14]. The oth-
er study supports the unidimensional structure of the PSQI,
while assuming a residual covariance between sleep duration
and habitual sleep efficiency [17]. In both studies, conclusions
resulted from CFA using a predefined factor structure and the
authors did not access the reliability of their factor solution,
which precludes direct comparisons with our findings.
In accordance with previous assessments of test-retest reli-
ability using a similar time interval between evaluations [16,
31, 32], we showed that the PSQI global score presented a
good degree of agreement. Furthermore, factor 2 also present-
ed an ICC equal or above 0.70, which may be interpreted as
corresponding to a good stability over the one-month period
between evaluations [30]. Among the PSQI components,
sleep disturbance presented the lowest agreement between
the two evaluations, which may, at least in part, result from
real changes in this sleep parameter, even in such a short
period, in breast cancer patients.
In our study, despite measures of sleep duration, habitual
sleep efficiency, and sleep disturbance correlated significantly
with the corresponding variables obtained from actigraphy,
we did not find a statistically significant or meaningful corre-
lation between objective and subjective measures of sleep
latency. In the present study, participants were asked to a keep
record of the time when they got into bed and the actigraphy
device that we used contains a photometer to measure light
exposure, which is useful for determining the time at which
Table 4 Spearman’s rho correlations of Pittsburgh Sleep Quality Index (PSQI) global and component scores with actigraphy measures and with other
theoretical related constructs
PSQI components Actigraphy (N = 61) Theoretical related constructs (N = 474)
Sleep
latency
Total sleep
time
Sleep
efficiency
WASO Sleep
complaints
Fatigue Anxiety Depression Global health
status/QoL
Sleep latency 0.11 0.15 0.05 0.00 0.45* 0.18* 0.24* 0.19* −0.23*
Sleep duration 0.09 −0.41* −0.30* 0.06 0.42* 0.05 0.13* 0.09* −0.12*
Habitual sleep efficiency 0.24 −0.07 −0.31* 0.27* 0.48* 0.14* 0.17* 0.16* −0.22*
Sleep disturbance 0.09 0.12 −0.18 0.39* 0.32* 0.24* 0.23* 0.18* −0.18*
Factor 1 (two-factor model) 0.16 −0.05 −0.15 0.16 0.61* 0.22* 0.28* 0.24* −0.31*
Factor 2 (two-factor model) −0.01 0.25 −0.01 0.22 0.35* 0.35* 0.42* 0.45* −0.44*
PSQI Global score (one-factor
model)
0.10 0.07 −0.09 0.17 0.62* 0.32* 0.39* 0.37* −0.42*
Higher scores of the PSQI components and of the PSQI global score correspond to worse outcomes, e.g., higher sleep latency, less sleep duration, less
habitual sleep efficiency, higher sleep disturbance, and worse sleep quality, as applicable. Higher scores of sleep latency andWASO actigraphy measures
correspond to a worse outcome, e.g., higher sleep latency and higher time awake after sleep onset, respectively; higher scores of total sleep time and sleep
efficiency actigraphy measures correspond to higher sleep time and higher sleep efficiency. Higher scores of sleep complaints, anxiety, depression, and
fatigue correspond to a worse outcome; higher scores of global health status/QoL represent better QoL
PSQI Pittsburgh Sleep Quality Index, QoL quality of life, WASO wake-up after sleep onset
*Correlation is significant at the 0.05 level
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the lights were turned off. However, the low accuracy of self-
reports may, at least in part, contribute to the underestimation
of the correlation between the two measures. The difficulty in
determining sleep onset latency accurately has been reported
before [33].
When the PSQI was developed, the authors acknowl-
edged that the clinical construct of sleep quality is a
Bcomplex phenomenon that is difficult to define and mea-
sure objectively^ and stated that despite including quanti-
tative aspects of sleep, as well as purely subjective as-
pects, such as Bdepth^ or Brestfulness^ of sleep, the exact
elements that compose sleep quality, and their relative
impor tance can vary between individuals [11] .
Therefore, it is reasonable to expect that the PSQI per-
forms differently in distinct settings or populations. Our
findings are consistent with other studies that have found
the PSQI global score to be more highly correlated with
psychological status than objective ones, such as those
derived from actigraphy [34–36]. In our study, the PSQI
global score correlated significantly with fatigue, anxiety,
depression, global health status/QoL, and especially with
sleep complaints. This suggests that, among breast cancer
patients, the PSQI scores may be more strongly correlated
with self-perceived sleep quality than with objective mea-
sures of sleep quality.
In addition to providing setting-specific data, our study
adds to previous research in the Portuguese population, the
evaluation of PSQI test-retest reliability and its construct va-
lidity using an objective sleep measure; the present study also
contributes to the characterization of the PSQI factor structure
and also for the measurement of its reliability and validity
among breast cancer patients. However, some limitations need
to be addressed. Our objective measure of sleep is a proxy
measurement, as polysomnography is still considered the gold
standard; nevertheless, previous studies have shown an agree-
ment between the two methods close to 90% [25–27]. Also,
the time period measured by the PSQI and that measured by
actigraphy were different; the PSQI was based on the month
prior to its completion and the actigraphy was performed in
the five days after PSQI testing, which may contribute to
underestimate the correlations between objective and subjec-
tive sleep measures. Finally, data were collected mainly in
early stage breast cancer patients, thus we cannot generalize
our results to women with more advanced disease and to ear-
lier periods after diagnosis.
In conclusion, our study provides additional evidence for
the good psychometric properties of the one-factor structure
of the European Portuguese version of the PSQI in breast
cancer patients. Despite the two-factor solution has demon-
strated better fit to the data, the unidimensional construct has
adequate reliability and validity, and the parsimonious solu-
tion may be used, both in clinical practice and research, to
identify Bgood^ and Bpoor^ sleepers. An inexpensive and
easy to administer psychometrically robust instrument to
evaluate sleep quality, such as the PSQI, can help clinicians
to comprehensively address the effect of sleep problems on
the well-being of breast cancer patients, as well as to provide
them with high quality care.
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